[1] |
ROCCO D, BATTILORO C, GRAVARA L D, et al. Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: first line treatment and beyond[J]. Rev Recent Clin Trials, 2019, 14(2): 120-128.
doi: 10.2174/1574887114666181205155211
|
[2] |
LEE D H. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures[J]. Pharmacol Ther, 2017, 174: 1-21.
doi: 10.1016/j.pharmthera.2017.02.001
|
[3] |
JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
doi: 10.3322/caac.20107
|
[4] |
CHEN W Q, ZHENG R S, ZHANG S W, et al. Report of incidence and mortality in China cancer registries, 2008[J]. Chung Kuo Yen Cheng Yen Chiu, 2012, 24(3): 171-180.
|
[5] |
GELATTI A C Z, DRILON A, SANTINI F C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2019, 137: 113-122.
doi: 10.1016/j.lungcan.2019.09.017
|
[6] |
NORONHA V, RAJENDRA A, JOSHI A, et al. Epidermal growth factor receptor-mutated non-small-cell lung cancer: a primer on contemporary management[J]. Cancer Res Stat Treat, 2019, 2(1): 36.
doi: 10.4103/CRST.CRST_51_19
|
[7] |
FUKUOKA M, WU Y L, THONGPRASERT S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin Oncol, 2011, 29(21): 2866-2874.
doi: 10.1200/JCO.2010.33.4235
|
[8] |
SHI Y K, WANG L, HAN B H, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J]. Ann Oncol, 2017, 28(10): 2443-2450.
doi: 10.1093/annonc/mdx359
|
[9] |
O’KANE G M, LIU G, STOCKLEY T L, et al. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance[J]. Lung Cancer, 2019, 131: 86-89.
doi: 10.1016/j.lungcan.2019.03.019
|
[10] |
GRAY J E, OKAMOTO I, SRIURANPONG V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer[J]. Clin Cancer Res, 2019, 25(22): 6644-6652.
doi: 10.1158/1078-0432.CCR-19-1126
|
[11] |
TRAN H T, LAM V K, ELAMIN Y Y, et al. Clinical outcomes in non-small-cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors and other targeted therapies based on tumor versus plasma genomic profiling[J]. JCO Precis Oncol, 2021, 5: PO.20.00532.
|
[12] |
LEDUC C, MERLIO J P, BESSE B, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program[J]. Ann Oncol, 2017, 28(11): 2715-2724.
doi: 10.1093/annonc/mdx404
|
[13] |
YANG J C H, WU Y L, SCHULER M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials[J]. Lancet Oncol, 2015, 16(2): 141-151.
doi: 10.1016/S1470-2045(14)71173-8
|
[14] |
BAE H M, LEE S H, KIM T M, et al. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis[J]. Lung Cancer Amsterdam Neth, 2012, 77(3): 572-577.
|
[15] |
CETIN K, CHRISTIANSEN C F, JACOBSEN J B, et al. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study[J]. Lung Cancer, 2014, 86(2): 247-254.
doi: 10.1016/j.lungcan.2014.08.022
|
[16] |
CHEN Y Y, WANG P P, FU Y, et al. Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors[J]. J Bone Oncol, 2021, 29: 100369.
|